23rd Apr 2018 07:00
23 April 2018
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Notice of Results
Venn Life Sciences (AIM: VENN) an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, will announce its audited preliminary results for the year ended 31 December 2017 on 17 May 2018.
The Company reaffirms its previous Trading Statement: 2017 was another solid year for Venn with the business delivering revenues of €17.8m (2016: €18.2m), broadly in line with market expectations, improved EBITDA performance and a closing cash position of €1.2m (2016: €3.4m).
Tony Richardson, Chief Executive Officer, and Christian Milla, Chief Operating Officer, will host a conference call and presentation for analysts at 09:30hrs BST at the offices of Walbrook PR. Details of the call will be published on the day of the results.
Enquiries:
Venn Life Sciences Holdings Plc Allan Wood, Non-Executive Chairman Tony Richardson, Chief Executive Officer
| Tel: +353 1 549 9341 | |
Cenkos (Nominated Advisor and Co-Broker) Mark Connelly/Steve Cox (Corporate Finance)
| Tel: +44 (0)20 3764 2341 | |
Davy (ESM Adviser and Co-Broker) Fergal Meegan / Matthew de Vere White (Corporate Finance)
| Tel: +353 1 679 6363 | |
Hybridan LLP (Co-Broker) Claire Louise Noyce
| Tel: +44 (0)20 3764 2341 | |
Walbrook PR Ltd | Tel: +44 (0)20 7933 8787 or [email protected] | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
Lianne Cawthorne | Mob: +44 (0)7584 391 303 | |
About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn has dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.
Further information in relation to Venn Life Sciences www.vennlifesciences.com
Related Shares:
ORPH.L